Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Porter

Showing results (41-50 of 99) with videos related to

Pageof 10
Sort By:
Physics in Medicine and Biology|June 8, 2000
The use of skin Fe levels as a surrogate marker for organ Fe levels, to monitor treatment in cases of iron overloadM J Farquharson, A P Bagshaw, J B Porter, et al.
Journal of Photochemistry and Photobiology. B, Biology|April 1, 1997
The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo studyS C Chang, A J MacRobert, J B Porter, et al.
Anaesthesia|April 10, 2002
A retrospective observational study of pre-operative sickle cell screeningP L Pemberton, J F Down, J B Porter, et al.
Annals of the New York Academy of Sciences|July 21, 1998
Selective loss of anterior pituitary volume with severe pituitary-gonadal insufficiency in poorly compliant male thalassemic patients with pubertal arrestR Chatterjee, M Katz, A Oatridge, et al.
Analytical Biochemistry|May 15, 1992
Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet-visible/radioactive detectionS Singh, N Mohammed, R Ackerman, et al.
Obstetrics and Gynecology|March 1, 1982
Oral contraceptives and nonfatal vascular disease--recent experienceJ B Porter, J R Hunter, D A Danielson, et al.
British Journal of Haematology|December 31, 1997
Non-transferrin-bound iron induced by myeloablative chemotherapyS J Bradley, I Gosriwitana, S Srichairatanakool, et al.
Blood|July 15, 1996
Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapyJ B Porter, R D Abeysinghe, L Marshall, et al.
Journal of Vascular Surgery|March 10, 2000
Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot studyS S Shoab, J B Porter, J H Scurr, et al.
Annals of the New York Academy of Sciences|July 21, 1998
A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicityJ B Porter, A Faherty, L Stallibrass, et al.
Pageof 10

Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
Physics in Medicine and Biology|June 8, 2000
The use of skin Fe levels as a surrogate marker for organ Fe levels, to monitor treatment in cases of iron overloadM J Farquharson, A P Bagshaw, J B Porter, et al.
Journal of Photochemistry and Photobiology. B, Biology|April 1, 1997
The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo studyS C Chang, A J MacRobert, J B Porter, et al.
Anaesthesia|April 10, 2002
A retrospective observational study of pre-operative sickle cell screeningP L Pemberton, J F Down, J B Porter, et al.
Annals of the New York Academy of Sciences|July 21, 1998
Selective loss of anterior pituitary volume with severe pituitary-gonadal insufficiency in poorly compliant male thalassemic patients with pubertal arrestR Chatterjee, M Katz, A Oatridge, et al.
Analytical Biochemistry|May 15, 1992
Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet-visible/radioactive detectionS Singh, N Mohammed, R Ackerman, et al.
Obstetrics and Gynecology|March 1, 1982
Oral contraceptives and nonfatal vascular disease--recent experienceJ B Porter, J R Hunter, D A Danielson, et al.
British Journal of Haematology|December 31, 1997
Non-transferrin-bound iron induced by myeloablative chemotherapyS J Bradley, I Gosriwitana, S Srichairatanakool, et al.
Blood|July 15, 1996
Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapyJ B Porter, R D Abeysinghe, L Marshall, et al.
Journal of Vascular Surgery|March 10, 2000
Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot studyS S Shoab, J B Porter, J H Scurr, et al.
Annals of the New York Academy of Sciences|July 21, 1998
A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicityJ B Porter, A Faherty, L Stallibrass, et al.
Pageof 10